Kidney CancerUroCCRNCT03293563
UroCCR Database: French Research Network for Kidney Cancer -UroCCR
An observational study of Kidney Cancer, run by University Hospital, Bordeaux at 68 sites in 4 countries.
Trial summary
Kidney cancer management has become increasingly complex with the diversification of treatment options and the integration of multidisciplinary care. To meet these challenges, the UroCCR network was established in France as a national registry and research platform dedicated to renal cancer. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Kidney Cancer
- What is being tested?
- Radical nephrectomy versus partial nephrectomy (according surgeon judgement)
- Type of treatment
- Surgery or procedure
- How many people
- 30,000 participants
- Where
- 68 sitesin 4 countries
- Study dates
- Dec 2011to Dec 2040
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with Kidney cancer
Who may be able to join
- Adult patient with kidney cancer
- Patient with no opposition to collection of its data for the study
Who cannot join
None listed.
Trial locations and contacts
68 sites in 4 countries. Contact the study team or a site near you to ask about taking part.
68 sites in 4 countries
France65 sites, 65 recruiting
- Recruiting
CHU Angers
Angers, 49100
Pierre BIGOT, Pr
- Recruiting
CHU Bordeaux
Bordeaux, 33076
Jean-Christophe BERNHARD, Pr
- Recruiting
Clinique TIVOLI-DUCOS
Bordeaux
Clément MICHIELS, Dr
- Recruiting
Polyclinique Médipôle Saint-Roch_Cabestany
Cabestany
Pierre GIMEL, Dr
- Recruiting
CHU Caen
Caen
Xavier TILLOU, Pr
- Not yet recruiting
Centre hospitalier Chalon sur Saône
Chalon-sur-Saône
Nicolas KOUTLIDIS, Dr
- Recruiting
CHU de Clermont-Ferrand
Clermont-Ferrand
Laurent GUY, Pr
- Not yet recruiting
Hôpitaux Civils de Colmar
Colmar
Jonathan THOUVENIN, Dr
- Recruiting
Ch Sud Francilien
Corbeil-Essonnes
Pietro GRANDE, Dr
- Not yet recruiting
Groupe Hospitalier Public du Sud de l'Oise
Creil
Fares KOSSEIFI, Dr
- Recruiting
CHU Henri Mondor - APHP
Créteil, 94010
Alexandre INGELS, Pr
- Recruiting
CHU de Dijon et CLCC Dijon
Dijon
Benjamin DELATTRE, Dr
- Recruiting
CH du Sud Seine et Marne
Fontainebleau
Karim BEN OTHMAN, Dr
- Not yet recruiting
Polyclinique d'Henin Beaumont
Hénin-Beaumont
Martin LORETTE, Dr
- Not yet recruiting
Centre Hospitalier Départemental de Vendée
La Roche-sur-Yon
Constance DEBOUDT-MACE, Dr
- Recruiting
CHU Grenoble
La Tronche, 38700
Jean-Luc DESCOTES, Pr
- Recruiting
Pôle Santé Sud
Le Mans
Olivier BELAS, Dr
- Not yet recruiting
Clinique Bon Secours-ELSAN
Le Puy-en-Velay, 43000
Marlène GUANDALINO, Dr
- Not yet recruiting
Hôpital Franco-Britannique,
Levallois-Perret
Caroline PETTENATI, Dr
- Recruiting
CH Libourne
Libourne
Benjamin ROUGET, Dr
- Recruiting
CHRU Lille - Centre Oscar Lambret
Lille, 59037
Jonathan OLIVIER, Pr
- Recruiting
Hôpital privé La Louvière
Lille
Charles BALLEREAU, Dr
- Recruiting
CHU Limoges
Limoges, 87042
Aurélien DESCAZEAUD
- Not yet recruiting
Clinique de l'Yvette
Longjumeau
Benjamin GABAY, Dr
- Recruiting
HCL Lyon
Lyon, 69002
Philippe PAPAREL, Pr
- Recruiting
APH Marseille
Marseille
Eric LECHEVALLIER, Pr
- Recruiting
Institut Paoli-Calmette
Marseille
Nicolas BRANGER, Dr
- Not yet recruiting
Grand Hôpital de l'Est Francilien
Meaux
Julien SARKIS, Dr
- Not yet recruiting
Centre Hospitalier d' Annecy Genevois
Metz
Arnoux VALENTIN, Dr
- Recruiting
CH Mont de Marsan
Mont-de-Marsan
Jean-Jacques PATARD, Pr
- Recruiting
Clinique du Pont de Chaume
Montauban
Jérôme GAS, Dr
- Not yet recruiting
CHU de Montpellier
Montpellier
Rodolphe THURET, Dr
- Recruiting
CHRU de Nancy
Nancy
Pascal ESCHWEGE, Pr
- Recruiting
CHU de Nantes
Nantes
Stéphane DE VERGIE, Dr
- Recruiting
CHU de Nice
Nice
Matthieu DURAND, Pr
- Recruiting
Clinique Saint George
Nice
Alexandre MARSAUD, Dr
- Recruiting
CHU de Nîmes
Nîmes
Alexis FONTENIL, Dr
- Recruiting
CHU d'Orléans
Orléans
Nicolas BRICHART, DR
- Recruiting
CHU Kremlin Bicêtre - APHP
Paris, 75013
Sébastien PARIER, Dr
- Recruiting
CH St Joseph
Paris, 75014
Xavier DURAND, Pr
- Recruiting
Hôpital Européen Georges Pompidou - APHP
Paris, 75015
François AUDENET, Dr
- Recruiting
CHU Tenon - APHP
Paris
Olivier TRAXER, Pr
- Recruiting
Hôpital Bichat -APHP
Paris
Evangelos Xylinas, Dr
- Recruiting
Hôpital Cochin Port-Royal - APHP
Paris
Julien ANRACT, Dr
- Recruiting
Hôpital Pitié Salpétrière - APHP
Paris
Morgan ROUPRET, Pr
- Not yet recruiting
Hôpital Saint Louis
Paris
Sonia BEBANE, Dr
- Not yet recruiting
Institut Mutualiste Montsouris
Paris
Mostefa BENNAMOUN, Dr
- Recruiting
Polyclinique Francheville
Périgueux
Richard MALLET, Dr
- Recruiting
Hôpital privé des Côtes d'Armor
Plérin
Fabien BOULIERE, Dr
- Recruiting
CHU Poitiers
Poitiers
Maxime VALLEE, Dr
- Recruiting
Hôpital privé Claude Galien
Quincy-sous-Sénart
Julien DEFONTAINES, Dr
- Recruiting
Clinique La Croix Du Sud
Quint-Fonsegrives
Jean-Baptiste BEAUVAL, Dr
- Recruiting
CHU Reims
Reims
Charlotte JONCOUR, Dr
- Recruiting
CHU Rennes - Centre Eugène Marquis
Rennes, 35000
Karim BENSALAH, Pr
- Recruiting
CHU Rouen
Rouen, 76031
Christian PFISTER, Pr
- Recruiting
CHU St-Etienne
Saint-Etienne
Lionel BADET, Pr
- Recruiting
Clinique Santé Atlantique de Nantes
Saint-Herblain
Quentin-Come LE CLERC, Dr
- Recruiting
Clinique Urologique Nantes Atlantis
Saint-Herblain
Lionel HOQUETIS, Dr
- Recruiting
Clinique Belledonne
Saint-Martin-d'Hères
Jean-Alexandre LONG, Pr
- Recruiting
CHU Strasbourg
Strasbourg, 67000
Hervé LANG, Pr
- Recruiting
ICANS
Strasbourg
Gabriel MALOUF, Pr
- Recruiting
CHU Toulouse - Centre Claudius Régaud
Toulouse, 31059
Nicolas DOUMERC, Dr
- Recruiting
Clinique Pasteur
Toulouse
Julien GUILLOTREAU, Dr
- Recruiting
CHRU Tours
Tours
Franck BRUYERE, Pr
- Not yet recruiting
Institut de Cancérologie lorraine
Vandœuvre-lès-Nancy
Sophie MARTIN, Dr
Belgium1 site, 1 recruiting
- Not yet recruiting
Hopital Universitaire de Bruxelles
Brussels
Thierry ROUMEGUERE, Pr
French Guiana1 site, 1 recruiting
- Recruiting
Centre Hospitalier de Kourou
Kourou
Vincent RAVERY, Pr
Reunion1 site, 1 recruiting
- Not yet recruiting
CHU Bellepierre
Saint-Denis
Davidson SYPRE, Dr
About this study
Official title: UroCCR Database: French Research Network for Kidney Cancer (National Multidisciplinary Clinical and Biological Database on Kidney Cancer)
Kidney cancer management has become increasingly complex with the diversification of treatment options and the integration of multidisciplinary care. To meet these challenges, the UroCCR network was established in France as a national registry and research platform dedicated to renal cancer. Funded by the French National Cancer Institute (INCa), UroCCR prospectively collects comprehensive real-world data on patient care and disease evolution, while systematically linking these records with annotated biological samples (plasma, urine, and both healthy and tumour tissues). For each case, more than one thousand variables may be recorded, covering clinical, imaging, and patient-reported information.
More than a registry, UroCCR is a collaborative network of clinical and research professionals using a shared, evolving tool that supports rapid implementation of studies and fosters active knowledge generation. Unlike retrospective registries or sample-centred biobanks, UroCCR offers prospective, patient-focused inclusion and a wide scope of investigation-from translational and technological research to clinical evaluation and social sciences. It also supports multiple ancillary studies, including retrospective analyses and prospective clinical or observational trials, and operates under a structured governance system with recognised national and international labels.
By combining a rigorously structured, multicentre dataset with linkage to the French national health data system (SNDS), the platform uniquely unites detailed clinical annotation with population-wide coverage, creating a high-value environment for advancing kidney cancer research and care.
Read the detailed description
The UroCCR project is a national kidney cancer registry and research network designed to address the specific challenges of renal cell carcinoma (RCC) management. While general cancer registries such as FRANCIM provide valuable surveillance data, most large-scale registries lack the depth of clinical, biological, and longitudinal follow-up information necessary to advance research and enable comprehensive analyses of kidney cancer outcomes. UroCCR was created in 2011 to meet this need.
With over 21,000 cases collected from 58 centres across France, UroCCR is now one of the largest national databases dedicated to kidney cancer worldwide. The registry captures detailed clinical parameters, treatments and outcomes, complemented by patient-reported measures and socioeconomic data. Because management practices within UroCCR follow the recommendations of the French Association of Urology (AFU), the dataset closely reflects real-world practice and provides a reliable basis for comparison with national and European guidelines. Moreover, patient data can be reused across numerous studies, allowing researchers to explore multiple scientific questions without requiring new enrolments for each project.
A distinctive strength of UroCCR is its integration of multiple research dimensions. Beyond clinical outcomes, it evaluates quality of life and the social and economic impact of kidney cancer. The registry is linked to annotated biobanking and national medico-administrative datasets, enabling translational studies and health services research. Additionally, UroCCR supports multiple ancillary studies, both retrospective analyses based on real-world data and prospective studies including randomised clinical trials or observational cohorts.
The project benefits from robust governance structures, ensuring standardised procedures, data quality, and ethical oversight. It has also received various national and international labels, recognising its methodological rigour and excellence in research infrastructure.
Digital innovations developed within the network, such as UroConnect® for perioperative monitoring and UroPredict machine learning models for recurrence and survival prediction, highlight its commitment to advancing care through new technologies.
At the national level, projects such as CARARE are developing personalised treatment strategies, including a molecular tumour board for non-clear cell RCC. Internationally, UroCCR is strengthening collaboration through partnerships with the European Association of Urology and the European Robotic Urology Section, contributing to harmonised data collection and large-scale multicentre research.
Ultimately, UroCCR functions as a dynamic research platform that unites clinicians, researchers, and patients around a shared infrastructure. By combining detailed clinical data with translational research, digital health tools, structured governance, recognised labels, and international partnerships, it aims to generate increasingly precise insights into RCC and to support the development of more effective, personalised treatment strategies in France and worldwide.
Objectives
- Promote research initiatives on this pathology by structuring national resources and skills,
- Create a multi-centre annotated collection of biological samples,
- Generate prospective research projects of all types and across various thematic fields,
- Allow any data controller who meets the necessary requirements to reuse the data contained therein for the purposes of research, evaluation or the advancement of knowledge in the following subject areas: 1-Descriptive epidemiology of kidney cancer; 2-Pharmaco-epidemiology and treatment monitoring: safety, efficacy, real-world treatment indications, costs; 3 -Quality of life and other 'patient-reported outcomes' and/or 'patient-reported experiences' (which may be collected automatically via digital methods using UroConnect), personal, family, professional and social consequences of kidney cancer; 4-Research into diagnostic, prognostic and predictive biomarkers; 5-Research into markers predictive of disease progression; 6-Evaluation of clinical practices and treatment techniques (surgical, interventional and drug-based) ; 7-Research related to the National Health Data System.
- Conditions
- Kidney Cancer
- Being tested
- Radical nephrectomy versus partial nephrectomy (according surgeon judgement)
- Keywords
- Kidney cancer, Surgical approaches, Medical treatment, Multicentric and multidisciplinary network
- Medical subject headings
- Kidney Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Radical nephrectomy versus partial nephrectomy (according surgeon judgement)Procedure or surgery
| Study group | Role | What they receive |
|---|---|---|
| Patients | Adult patients with kidney cancer Receives: Procedure: Radical nephrectomy versus partial nephrectomy (according surgeon judgement) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Promotion of Prospective Research Projects
Development and conduct of prospective research projects across a broad range of thematic fields related to kidney cancer .
Measured: From patient enrollment (Day 0) until the end of follow-up (death or withdrawal from the study).
Secondary outcomes (7)
Establishment of a Multicentre Annotated Biological Sample Collection
Annotation of biological samples collection and associated clinical data to support translational and clinical research in kidney cancer.
Measured: From patient enrollment (Day 0) until the end of follow-up (death or withdrawal from the study).
Advancement of Knowledge in Kidney Cancer Descriptive Epidemiology
Characterization of the incidence, prevalence, distribution, and trends of kidney cancer within the population
Measured: From patient enrollment (Day 0) until the end of follow-up (death or withdrawal from the study).
Advancement of Knowledge in Pharmacoepidemiology and Treatment Monitoring in Kidney Cancer
Evaluatation of treatment safety, efficacy, real-world indications, utilization patterns, and associated healthcare costs
Measured: From patient enrollment (Day 0) until the end of follow-up (death or withdrawal from the study).
Advancement of Knowledge in Quality of Life and Patient-Reported Outcomes in Kidney Cancer
Assessment of quality of life, patient-reported outcomes (PROs), and patient-reported experiences (PREs), including the personal, familial, professional, and social impact of kidney cancer. Data may be collected through digital tools such as UroConnect
Measured: From patient enrollment (Day 0) until the end of follow-up (death or withdrawal from the study).
Diagnostic, Prognostic, and Predictive Biomarker Research
Identification and validation of biomarkers for diagnosis, prognosis, and prediction of treatment response in kidney cancer
Measured: From patient enrollment (Day 0) until the end of follow-up (death or withdrawal from the study).
Evaluation of Clinical Practices and Treatment Strategies
Assessment of surgical, interventional, and pharmacological treatment approaches to improve clinical practice and patient outcomes.
Measured: From patient enrollment (Day 0) until the end of follow-up (death or withdrawal from the study).
Research Using National Health Data System Data
Conduct of studies using data from the National Health Data System to support epidemiological, clinical, and health services research
Measured: From patient enrollment (Day 0) until the end of follow-up (death or withdrawal from the study).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Sep 2017
- Study startDec 2011
- Primary completionDec 2040 (estimated)
- Study completionDec 2040 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Kidney CancerStudies of the same condition, open and under way.
- More trials run by University Hospital, BordeauxThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 30,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Bordeaux
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Jean-Christophe BERNHARD, PHU, Principal investigator, University Hospital, Bordeaux
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03293563
- Sponsor's protocol ID
- CHUBX 2011/38
- Acronym
- UroCCR
- Status last verified
- Sep 2025
- First submitted
- 12 Jul 2016
- Last updated
- 25 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Publications
Binzaqr S, Kryza D, Giraudet AL, Bernhard JC, Gross-Goupil M, Yacoub M, Margue G, Hindie E, Morgat C. Prostate-specific membrane antigen (PSMA) expression in primary and metastatic renal cell cancer (UroCCR-65 study). EJNMMI Res. 2025 Apr 9;15(1):38. doi: 10.1186/s13550-025-01232-8.
PubMed 40205264Ingels A, Bensalah K, Beauval JB, Paparel P, Roupret M, Lang H, Nouhaud FX, Henon F, Bruyere F, Audenet F, Lebacle C, Baumert H, Long JA, Tambwe R, Charles T, Xylinas E, Waeckel T, Michiels C, Asselineau J, Benard A, Margue G, Boissier R, Bigot P, Bernhard JC; Comite Cancer de l'Association Francaise d'Urologie (CCAFU). Comparison of open and robotic-assisted partial nephrectomy approaches using multicentric data (UroCCR-47 study). Sci Rep. 2022 Nov 8;12(1):18981. doi: 10.1038/s41598-022-22912-8.
PubMed 36347900Morrone A, Bentellis I, Bernhard JC, Bensalah K, Champy C, Bruyere F, Doumerc N, Olivier J, Audenet F, Parier B, Brenier M, Long JA, Nouhaud FX, Branger N, Lang H, Charles T, Xylinas E, Waeckel T, Gomez F, Boissier R, Rouget B, Shaikh A, Chevallier D, Ambrosetti D, Durand M. Positive surgical margin's impact on short-term oncological prognosis after robot-assisted partial nephrectomy (MARGINS study: UroCCR no 96). Sci Rep. 2022 Oct 31;12(1):18342. doi: 10.1038/s41598-022-23146-4.
PubMed 36316438Brehier G, Bouvier A, Besnier L, Willoteaux S, Nedelcu C, Culty T, Aube C, Bigot P. Renal function after partial nephrectomy following intra-arterial embolization of renal tumors. Sci Rep. 2020 Dec 7;10(1):21352. doi: 10.1038/s41598-020-78461-5.
PubMed 33288819
Study at a glance
From the registry record, last updated by the sponsor on 25 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- UroCCR Database: French Research Network for Kidney Cancer (National Multidisciplinary Clinical and Biological Database on Kidney Cancer)
- ClinicalTrials.gov ID
- NCT03293563
- Acronym / sponsor ID
- UroCCR / CHUBX 2011/38
- Conditions
- Kidney Cancer
- Keywords
- Kidney cancer, Surgical approaches, Medical treatment, Multicentric and multidisciplinary network
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 30,000 participants (estimated)
- Lead sponsor
- University Hospital, BordeauxUniversity, hospital or other
- Study start
- Dec 2011
- Primary completion
- Dec 2040 (estimated)
- Study completion
- Dec 2040 (estimated)
- First posted
- 26 Sep 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Kidney cancer management has become increasingly complex with the diversification of treatment options and the integration of multidisciplinary care. To meet these challenges, the UroCCR network was established in France as a national registry and research platform dedicated to renal cancer. Funded by the French National Cancer Institute (INCa), UroCCR prospectively collects comprehensive real-world data on patient care and disease evolution, while systematically linking these records with annotated biological samples (plasma, urine, and both healthy and tumour tissues). For each case, more than one thousand variables may be recorded, covering clinical, imaging, and patient-reported information.
More than a registry, UroCCR is a collaborative network of clinical and research professionals using a shared, evolving tool that supports rapid implementation of studies and fosters active knowledge generation. Unlike retrospective registries or sample-centred biobanks, UroCCR offers prospective, patient-focused inclusion and a wide scope of investigation-from translational and technological research to clinical evaluation and social sciences. It also supports multiple ancillary studies, including retrospective analyses and prospective clinical or observational trials, and operates under a structured governance system with recognised national and international labels.
By combining a rigorously structured, multicentre dataset with linkage to the French national health data system (SNDS), the platform uniquely unites detailed clinical annotation with population-wide coverage, creating a high-value environment for advancing kidney cancer research and care.
Detailed description
The UroCCR project is a national kidney cancer registry and research network designed to address the specific challenges of renal cell carcinoma (RCC) management. While general cancer registries such as FRANCIM provide valuable surveillance data, most large-scale registries lack the depth of clinical, biological, and longitudinal follow-up information necessary to advance research and enable comprehensive analyses of kidney cancer outcomes. UroCCR was created in 2011 to meet this need.
With over 21,000 cases collected from 58 centres across France, UroCCR is now one of the largest national databases dedicated to kidney cancer worldwide. The registry captures detailed clinical parameters, treatments and outcomes, complemented by patient-reported measures and socioeconomic data. Because management practices within UroCCR follow the recommendations of the French Association of Urology (AFU), the dataset closely reflects real-world practice and provides a reliable basis for comparison with national and European guidelines. Moreover, patient data can be reused across numerous studies, allowing researchers to explore multiple scientific questions without requiring new enrolments for each project.
A distinctive strength of UroCCR is its integration of multiple research dimensions. Beyond clinical outcomes, it evaluates quality of life and the social and economic impact of kidney cancer. The registry is linked to annotated biobanking and national medico-administrative datasets, enabling translational studies and health services research. Additionally, UroCCR supports multiple ancillary studies, both retrospective analyses based on real-world data and prospective studies including randomised clinical trials or observational cohorts.
The project benefits from robust governance structures, ensuring standardised procedures, data quality, and ethical oversight. It has also received various national and international labels, recognising its methodological rigour and excellence in research infrastructure.
Digital innovations developed within the network, such as UroConnect® for perioperative monitoring and UroPredict machine learning models for recurrence and survival prediction, highlight its commitment to advancing care through new technologies.
At the national level, projects such as CARARE are developing personalised treatment strategies, including a molecular tumour board for non-clear cell RCC. Internationally, UroCCR is strengthening collaboration through partnerships with the European Association of Urology and the European Robotic Urology Section, contributing to harmonised data collection and large-scale multicentre research.
Ultimately, UroCCR functions as a dynamic research platform that unites clinicians, researchers, and patients around a shared infrastructure. By combining detailed clinical data with translational research, digital health tools, structured governance, recognised labels, and international partnerships, it aims to generate increasingly precise insights into RCC and to support the development of more effective, personalised treatment strategies in France and worldwide.
Objectives
- Promote research initiatives on this pathology by structuring national resources and skills,
- Create a multi-centre annotated collection of biological samples,
- Generate prospective research projects of all types and across various thematic fields,
- Allow any data controller who meets the necessary requirements to reuse the data contained therein for the purposes of research, evaluation or the advancement of knowledge in the following subject areas: 1-Descriptive epidemiology of kidney cancer; 2-Pharmaco-epidemiology and treatment monitoring: safety, efficacy, real-world treatment indications, costs; 3 -Quality of life and other 'patient-reported outcomes' and/or 'patient-reported experiences' (which may be collected automatically via digital methods using UroConnect), personal, family, professional and social consequences of kidney cancer; 4-Research into diagnostic, prognostic and predictive biomarkers; 5-Research into markers predictive of disease progression; 6-Evaluation of clinical practices and treatment techniques (surgical, interventional and drug-based) ; 7-Research related to the National Health Data System.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients | – | Procedure: Radical nephrectomy versus partial nephrectomy (according surgeon judgement)Adult patients with kidney cancer |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with Kidney cancer
Key inclusion criteria (2 listed)
- Adult patient with kidney cancer
- Patient with no opposition to collection of its data for the study
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Radical nephrectomy versus partial nephrectomy (according surgeon judgement) | Procedure or surgery | Patients |
Primary outcome
Promotion of Prospective Research Projects
Time frame: From patient enrollment (Day 0) until the end of follow-up (death or withdrawal from the study).
Development and conduct of prospective research projects across a broad range of thematic fields related to kidney cancer .
7 secondary outcomes
Establishment of a Multicentre Annotated Biological Sample Collection
Time frame: From patient enrollment (Day 0) until the end of follow-up (death or withdrawal from the study).
Advancement of Knowledge in Kidney Cancer Descriptive Epidemiology
Time frame: From patient enrollment (Day 0) until the end of follow-up (death or withdrawal from the study).
Advancement of Knowledge in Pharmacoepidemiology and Treatment Monitoring in Kidney Cancer
Time frame: From patient enrollment (Day 0) until the end of follow-up (death or withdrawal from the study).
Advancement of Knowledge in Quality of Life and Patient-Reported Outcomes in Kidney Cancer
Time frame: From patient enrollment (Day 0) until the end of follow-up (death or withdrawal from the study).
Diagnostic, Prognostic, and Predictive Biomarker Research
Time frame: From patient enrollment (Day 0) until the end of follow-up (death or withdrawal from the study).
Evaluation of Clinical Practices and Treatment Strategies
Time frame: From patient enrollment (Day 0) until the end of follow-up (death or withdrawal from the study).
Research Using National Health Data System Data
Time frame: From patient enrollment (Day 0) until the end of follow-up (death or withdrawal from the study).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Jun 2026.
- Derived from this study: PubMed 40205264Binzaqr S, Kryza D, Giraudet AL, Bernhard JC, Gross-Goupil M, Yacoub M, Margue G, Hindie E, Morgat C. Prostate-specific membrane antigen (PSMA) expression in primary and metastatic renal cell cancer (UroCCR-65 study). EJNMMI Res. 2025 Apr 9;15(1):38. doi: 10.1186/s13550-025-01232-8.
- Derived from this study: PubMed 36347900Ingels A, Bensalah K, Beauval JB, Paparel P, Roupret M, Lang H, Nouhaud FX, Henon F, Bruyere F, Audenet F, Lebacle C, Baumert H, Long JA, Tambwe R, Charles T, Xylinas E, Waeckel T, Michiels C, Asselineau J, Benard A, Margue G, Boissier R, Bigot P, Bernhard JC; Comite Cancer de l'Association Francaise d'Urologie (CCAFU). Comparison of open and robotic-assisted partial nephrectomy approaches using multicentric data (UroCCR-47 study). Sci Rep. 2022 Nov 8;12(1):18981. doi: 10.1038/s41598-022-22912-8.
- Derived from this study: PubMed 36316438Morrone A, Bentellis I, Bernhard JC, Bensalah K, Champy C, Bruyere F, Doumerc N, Olivier J, Audenet F, Parier B, Brenier M, Long JA, Nouhaud FX, Branger N, Lang H, Charles T, Xylinas E, Waeckel T, Gomez F, Boissier R, Rouget B, Shaikh A, Chevallier D, Ambrosetti D, Durand M. Positive surgical margin's impact on short-term oncological prognosis after robot-assisted partial nephrectomy (MARGINS study: UroCCR no 96). Sci Rep. 2022 Oct 31;12(1):18342. doi: 10.1038/s41598-022-23146-4.
- Derived from this study: PubMed 33288819Brehier G, Bouvier A, Besnier L, Willoteaux S, Nedelcu C, Culty T, Aube C, Bigot P. Renal function after partial nephrectomy following intra-arterial embolization of renal tumors. Sci Rep. 2020 Dec 7;10(1):21352. doi: 10.1038/s41598-020-78461-5.
- Program I.Care BordeauxLink provided by the sponsor.
- UroPredict AlgorithmLink provided by the sponsor.
- UroCCR websiteLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Kidney Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
Active, not recruitingPhase 3
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Carcinoma, Renal Cell
RecruitingPhase 2/3
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma
Not yet recruitingPhase 2
Toripalimab and Lenvatinib With or Without SBRT Before Surgery for Non-Clear Cell Kidney Cancer
Nonmetastatic Locally Advanced Non-Clear Cell Renal Cell Carcinoma
Not yet recruitingPhase 1
A Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Advanced Cancer and Hepatic or Renal Impairment
Relapsed/Refractory (R/R) Hematologic Malignancies, Acute Leukemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Jean-Christophe BERNHARD, PHU principal investigator
University Hospital, Bordeaux
68 sites in 4 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Kidney Cancer, run by University Hospital, Bordeaux at 68 sites in 4 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 25 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 68 sites in France, Belgium, French Guiana, Reunion. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jean-Christophe BERNHARD, PHU (+33 (0)5 57 82 03 50, jean-christophe.bernhard@chu-bordeaux.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Promotion of Prospective Research Projects (time frame: From patient enrollment (Day 0) until the end of follow-up (death or withdrawal from the study).). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03293563, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jun 2026.